Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA …
Over the last 12 months, insiders at Lantern Pharma Inc. have bought $0 and sold $3.23M worth of Lantern Pharma Inc. stock.
On average, over the past 5 years, insiders at Lantern Pharma Inc. have bought $150,000 and sold $3.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $150,000 was made by KEYSER D JEFFREY (director) on 2020‑06‑11.
2024-05-24 | Sale | 10 percent owner | 20,000 0.1889% | $6.33 | $126,600 | -37.64% | ||
2024-05-24 | Sale | 10 percent owner | 20,000 0.1889% | $6.33 | $126,600 | -37.64% | ||
2024-05-23 | Sale | 10 percent owner | 10,000 0.0932% | $6.25 | $62,500 | -35.90% | ||
2024-05-23 | Sale | 10 percent owner | 10,000 0.0932% | $6.25 | $62,500 | -35.90% | ||
2024-02-29 | Sale | 10 percent owner | 19,703 0.1653% | $4.87 | $95,954 | -3.33% | ||
2024-02-29 | Sale | 10 percent owner | 19,703 0.1653% | $4.87 | $95,954 | -3.33% | ||
2024-02-28 | Sale | 10 percent owner | 74,297 0.6556% | $4.85 | $360,340 | -8.82% | ||
2024-02-28 | Sale | 10 percent owner | 74,297 0.6556% | $4.85 | $360,340 | -8.82% | ||
2024-02-27 | Sale | 10 percent owner | 50,000 0.4668% | $4.40 | $220,000 | +3.78% | ||
2024-02-27 | Sale | 10 percent owner | 50,000 0.4668% | $4.40 | $220,000 | +3.78% | ||
2024-01-17 | Sale | 10 percent owner | 58,889 0.6101% | $4.20 | $247,334 | +15.62% | ||
2024-01-17 | Sale | 10 percent owner | 58,889 0.6101% | $4.20 | $247,334 | +15.62% | ||
2023-11-29 | Sale | 10 percent owner | 145,348 1.1501% | $3.44 | $499,997 | +7.93% | ||
2023-11-29 | Sale | 10 percent owner | 145,348 1.1501% | $3.44 | $499,997 | +7.93% | ||
2022-11-08 | Sale | director | 350,000 3.233% | $4.40 | $1.54M | +13.90% | ||
2022-11-08 | Sale | director | 350,000 3.233% | $4.40 | $1.54M | +13.90% | ||
2022-09-02 | Sale | 1,275 0.0118% | $5.20 | $6,630 | -3.08% | |||
2022-09-02 | Sale | 1,275 0.0118% | $5.20 | $6,630 | -3.08% | |||
2020-06-11 | director | 10,000 0.369% | $15.00 | $150,000 | +5.48% |
KEYSER D JEFFREY | director | 10000 0.0927% | $3.08 | 1 | 0 | +5.48% |
The Vanguard Group | $3.2M | 3.38 | 363,720 | -0.44% | -$14,203.20 | <0.0001 | |
Newedge Advisors Llc | $1.41M | 1.49 | 160,532 | -3.28% | -$47,872.08 | 0.01 | |
Geode Capital Management | $769,065.00 | 0.81 | 87,374 | -8.06% | -$67,440.84 | <0.0001 | |
Renaissance Technologies | $578,000.00 | 0.61 | 65,700 | +50% | +$192,666.67 | <0.01 | |
Cm Management Llc | $572,000.00 | 0.6 | 65,000 | -18.75% | -$132,000.00 | 0.01 |